Učitavanje...
Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura
Patients with severe autoimmune thrombotic thrombocytopenic purpura (TTP) experience acute hematologic emergencies during disease flares and a lifelong threat for relapse. Rituximab, in addition to steroids and therapeutic plasma exchange (TPE), has been shown to mitigate relapse risk. A barrier to...
Spremljeno u:
| Izdano u: | Blood Adv |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7013262/ https://ncbi.nlm.nih.gov/pubmed/32045473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000827 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|